PBH — Prestige Consumer Healthcare Inc.

NYSE · Health Care · Pharmaceuticals · CIK 1295947 ·
Last close
$48.02
Market Cap
$2.27B
52W High
$70.02
52W Low
$42.62
ADV30
695,440
Next earnings
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 281,617,000 146,299,000 75,492,000 53,928,000 3,494,313,000 63,868,000 1,606,797,000
Dec 2025 283,444,000 157,369,000 82,491,000 46,696,000 3,494,743,000 62,373,000 1,665,292,000
Sep 2025 274,114,000 151,579,000 79,670,000 42,211,000 3,442,280,000 119,106,000 1,617,311,000
Jun 2025 249,530,000 140,331,000 71,756,000 47,466,000 3,431,625,000 139,502,000 1,576,143,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$276,634,000
Investing CF
$-136,906,000
Financing CF
$-129,451,000
CapEx
$-9,447,000
Dividends Paid
Buybacks
$-166,906,000
EPS Diluted TTM
$4.00
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$1,692,175,000
Inventory
$163,594,000
Receivables
$190,456,000
ST Investments
EBIT TTM
$308,353,000
Pretax Income TTM
$266,683,000
Interest Exp TTM
$41,670,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,088,705,024
EBITDA
$340,681,984
Free Cash Flow
$192,759,744
Enterprise Value
$3,255,424,000
Total Cash
$63,868,000
Total Debt
$1,045,427,968
Shares Out
47,372,166
Trailing EPS
$3.91
Book Value
$38.66
ROE
10.2%
ROA
5.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 1,088,705,000 309,409,000 190,301,000 3,494,313,000 1,606,797,000 257,627,000
Mar 2025 1,137,762,000 349,241,000 214,605,000 3,402,218,000 1,567,321,000 251,515,000
Mar 2024 1,125,357,000 342,429,000 209,339,000 3,318,417,000 1,663,333,000 248,926,000
Mar 2023 1,127,725,000 347,802,000 -82,306,000 3,353,729,000 1,906,645,000 229,716,000

TTM Snapshot

Revenues TTM
$1,123,052,000
NetIncome TTM
$216,244,000
OpCashFlow TTM
$0
Assets (Latest)
$3,402,218,000
Forward EPS
$5.07

Peers — same industry

TickerNameMarket CapLastDaily %
RARE Ultragenyx Pharmaceutical Inc. $2.28B $23.14
GIFOF Grifols SA $2.29B $8.85
NKTR NEKTAR THERAPEUTICS $2.22B $65.56
KNSA Kiniksa Pharmaceuticals International, plc $2.45B $52.86
VERA Vera Therapeutics, Inc. $2.47B $34.34

News headlines (Yahoo Finance, 1h cache)

Prestige Consumer Healthcare Inc. Just Missed Earnings - But Analysts Have Updated Their Models
2026-05-15 12:50 · Yahoo
Prestige Consumer Healthcare Q4 Earnings Call Highlights
2026-05-15 07:07 · Yahoo
Prestige Consumer Healthcare Inc (PBH) Q4 2026 Earnings Call Highlights: Navigating Challenges ...
2026-05-14 23:02 · Yahoo
Sector Update: Healthcare Stocks Mixed Late Afternoon
2026-05-14 19:48 · Yahoo
Prestige Consumer Healthcare Attributes Soft Results to Low Eye Care Sales, Weak Consumer Backdrop
2026-05-14 17:44 · Yahoo
Sector Update: Healthcare Stocks Softer Thursday Afternoon
2026-05-14 17:43 · Yahoo
PBH Q4 Earnings & Revenues Miss Estimates, Margins Down
2026-05-14 17:08 · Yahoo
Prestige Consumer Faces Execution Pressure After Weak Q4, Softer 2026 Outlook, Oppenheimer Says
2026-05-14 15:13 · Yahoo
Prestige Consumer Healthcare (PBH) Q4 Earnings and Revenues Lag Estimates
2026-05-13 22:10 · Yahoo
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say
2026-05-13 22:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.